|
|
||||||||
J Thorac Cardiovasc Surg 2004;128:245-253
© 2004 The American Association for Thoracic Surgery
Cardiopulmonary support and physiology |
a Department of Cardiovascular Surgery, European Hospital Georges Pompidou, Paris, France
Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.
Received for publication November 24, 2003; revisions received February 2, 2004; revisions received February 24, 2004; accepted for publication April 1, 2004.
* Address for reprints: Juan C. Chachques, MD, PhD, Department of Cardiac Surgery, Pompidou Hospital, 20 rue Leblanc, 75015 Paris, France
j.chachques{at}brs.ap-hop-paris.fr
BACKGROUND: Locally delivered angiogenic growth factors and cell implantation have been proposed for patients with myocardial infarcts without a possibility of percutaneous or surgical revascularization. The goal of this study was to compare the effects of these techniques in an experimental model of myocardial infarct.
METHODS: Left ventricular myocardial infarction was created in 27 sheep by ligation of 2 coronary arteries. Three weeks after creation of the infarct, animals were randomized into 4 groups. In group 1, sheep received a culture medium injection to the infarct area (control group); group 2 underwent autologous myoblast implantation; group 3 received vascular endothelial growth factor; and group 4 received injection of both vascular endothelial growth factor and myoblasts. Evaluation included serum troponin IC levels, echocardiography (2-dimensional and color kinesis), and immunohistologic studies for quantitative analysis of capillaries (3 months after surgery).
RESULTS: Four animals died of refractory ventricular fibrillation during myocardial infarction; 2 died after surgery because of stroke and 2 because of infections. Serum troponin increased to 45.6 ± 4.7 ng/mL at postinfarction day 2. Echocardiography at 3 months showed a significant limitation of left ventricular dilation in the cell group (57 ± 11.1 mL) and in the cell plus vascular endothelial growth factor group (58.6 ± 6.6 mL: control group, 74.4 ± 11.2 mL; vascular endothelial growth factor group, 68.1 ± 3.4 mL). Color kinesis echography showed important improvements of regional fractional area change in the cell group (from 13.6% ± 0.8% to 21.1% ± 1.5%) and in the cell plus vascular endothelial growth factor group (from 12.8% ± 0.9% to 18.7% ± 2.3%). The number of capillaries increased in the peri-infarct region of the vascular endothelial growth factor group (1036 ± 75: control group, 785 ± 31; cell group, 830 ± 75; cell plus vascular endothelial growth factor group, 831 ± 83).
CONCLUSIONS: In the cell therapy groups, regional ventricular contractility improved and heart dilatation was limited compared with either vascular endothelial growth factor or control; thus, postischemic remodeling was reduced. Angiogenesis was demonstrated in the vascular endothelial growth factor group, without improvement of ventricular function and remodeling. To improve local conditions for cell survival, further studies are warranted on prevascularization of myocardial scars with angiogenic therapy.
This article has been cited by other articles:
![]() |
J. C. Chachques, J. C. Trainini, N. Lago, M. Cortes-Morichetti, O. Schussler, and A. Carpentier Myocardial Assistance by Grafting a New Bioartificial Upgraded Myocardium (MAGNUM Trial): Clinical Feasibility Study Ann. Thorac. Surg., March 1, 2008; 85(3): 901 - 908. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kondoh, Y. Sawa, N. Fukushima, G. Matsumiya, S. Miyagawa, S. Kitagawa-Sakakida, Y. Imanishi, N. Kawaguchi, N. Matsuura, and H. Matsuda Combined Strategy Using Myoblasts and Hepatocyte Growth Factor in Dilated Cardiomyopathic Hamsters Ann. Thorac. Surg., July 1, 2007; 84(1): 134 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Choi, K.-B. Kim, W. Han, D. S. Kim, J. S. Park, J. J. Lee, and D. S. Lee Efficacy of Therapeutic Angiogenesis by Intramyocardial Injection of pCK-VEGF165 in Pigs Ann. Thorac. Surg., August 1, 2006; 82(2): 679 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kanamori, G. Watanabe, T. Yasuda, H. Nagamine, H. Kamiya, and Y. Koshida Hybrid Surgical Angiogenesis: Omentopexy Can Enhance Myocardial Angiogenesis Induced by Cell Therapy Ann. Thorac. Surg., January 1, 2006; 81(1): 160 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sesti, S. L. Hale, C. Lutzko, and R. A. Kloner Granulocyte Colony-Stimulating Factor and Stem Cell Factor Improve Contractile Reserve of the Infarcted Left Ventricle Independent of Restoring Muscle Mass J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1662 - 1669. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C Chachques, C. Salanson-Lajos, P. Lajos, A. Shafy, A. Alshamry, and A. Carpentier Cellular Cardiomyoplasty for Myocardial Regeneration Asian Cardiovasc Thorac Ann, September 1, 2005; 13(3): 287 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fazel, G. H.L. Tang, D. Angoulvant, M. Cimini, R. D. Weisel, R.-K. Li, and T. M. Yau Current Status of Cellular Therapy for Ischemic Heart Disease Ann. Thorac. Surg., June 1, 2005; 79(6): S2238 - S2247. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K. Rosengart, E. G. Chedrawy, G. Patejunas, and M. Retuarto Vascular endothelial growth factor before cells J. Thorac. Cardiovasc. Surg., March 1, 2005; 129(3): 696 - 696. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |